Fractyl Health, Inc. (NASDAQ:GUTS) Stock Has Consensus Price Target of $66.00

Fractyl Health, Inc. (NASDAQ:GUTS) has earned a consensus rating of “Hold” from the five ratings firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $50.25.

A number of research firms have recently commented on GUTS. Craig Hallum set a $5.00 price target on shares of Fractyl Health in a research report on Monday. Wall Street Zen downgraded shares of Fractyl Health from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Weiss Ratings downgraded shares of Fractyl Health from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, September 3rd. Finally, Morgan Stanley lowered their target price on shares of Fractyl Health to $4.00 and set an “equal weight” rating on the stock in a research note on Monday.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of GUTS. Nantahala Capital Management LLC bought a new position in shares of Fractyl Health in the second quarter worth about $8,968,058. General Catalyst Group Management LLC acquired a new position in shares of Fractyl Health during the 2nd quarter worth about $3,880,000. Bank of America Corp DE acquired a new position in shares of Fractyl Health during the 2nd quarter worth about $4,791,000. Sanctuary Advisors LLC acquired a new position in shares of Fractyl Health during the 2nd quarter worth about $26,000. Finally, PEAK6 LLC bought a new stake in Fractyl Health during the 2nd quarter valued at approximately $159,000.

Fractyl Health Stock Down 11.0%

Shares of GUTS stock opened at $1.38 on Tuesday. The stock’s 50 day simple moving average is $6.75 and its 200 day simple moving average is $8.03. The company has a debt-to-equity ratio of 1.41, a quick ratio of 3.15 and a current ratio of 3.15. Fractyl Health has a twelve month low of $1.37 and a twelve month high of $29.34. The company has a market capitalization of $18.30 million, a price-to-earnings ratio of -0.13 and a beta of 2.42.

Fractyl Health (NASDAQ:GUTS) last posted its earnings results on Monday, August 10th. The company reported ($1.44) earnings per share for the quarter, topping the consensus estimate of ($1.62) by $0.18. As a group, research analysts predict that Fractyl Health will post -6.32 EPS for the current year.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage biotechnology company focused on developing therapies for metabolic diseases, including type 2 diabetes and obesity. The company’s approach is based on targeting the biology of the gastrointestinal system and developing treatments intended to address underlying disease mechanisms rather than relying solely on chronic medication.

Fractyl Health’s lead product candidate is Revita, an investigational, minimally invasive endoscopic procedure designed to resurface the duodenal lining.